SynthesisNeurobiology of aging2021
KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.
Open access · greenAbstract readMeta-Analysis
In one paragraph
Synthesis in Neurobiology of aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Humanized Klotho haplotypes cause widespread transcriptomic changes in mouse brain.bioRxiv : the preprint server for biology · 2026Article
- Article
- KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance in Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers.Journal of Alzheimer's disease : JAD · 2025Article
- Association between Klotho levels in cerebrospinal fluid and choroid plexus enlargement in neurodegeneration.Frontiers in aging neuroscience · 2025Article
- Amyloid-β positivity is less prevalent in cognitively unimpairedJournal of Alzheimer's disease : JAD · 2024Article
- Towards cascading genetic risk in Alzheimer's disease.Brain : a journal of neurology · 2024Article
- The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Oligodendrocyte progenitor cells in Alzheimer's disease: from physiology to pathology.Translational neurodegeneration · 2023Review
- Longevity factor klotho enhances cognition in aged nonhuman primates.Nature aging · 2023Article
- Interaction betweenGenes · 2023Article
- Association of Klotho Protein Levels and KL-VS Heterozygosity With Alzheimer Disease and Amyloid and Tau Burden.JAMA network open · 2022Article
- Myelin repair in Alzheimer's disease: a review of biological pathways and potential therapeutics.Translational neurodegeneration · 2022Review
- Translational approaches to understanding resilience to Alzheimer's disease.Trends in neurosciences · 2022Review
- Article
- Circulating Klotho Is Higher in Cerebrospinal Fluid than Serum and Elevated Among KLOTHO Heterozygotes in a Cohort with Risk for Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 7 institutions in 3 countries.
Michael E BelloyDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA. Electronic address: mbelloy@stanford.edu.
Sarah J EgerDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Yann Le GuenDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Valerio NapolioniDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Kacie D DetersDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Hyun-Sik YangDepartment of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Marzia A ScelsiCentre for Medical Image Computing (CMIC), University College London, London, UK.
Tenielle PorterCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.
Sarah-Naomi JamesMedical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK.
Andrew WongMedical Research Council Unit for Lifelong Health and Ageing, University College London, London, UK.
Jonathan M SchottDementia Research Centre, University College London Queen Square Institute of Neurology, University College London, London, UK; UK Dementia Research Institute, University College London, London, UK.
Reisa A SperlingDepartment of Neurology, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Simon M LawsCollaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.
Elisabeth C MorminoDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
Zihuai HeDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA; Department of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA.
Summer S HanDepartment of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, CA, USA; Department of Neurosurgery, Stanford University, Stanford, CA, USA.
Andre AltmannCentre for Medical Image Computing (CMIC), University College London, London, UK.
Michael D GreiciusDepartment of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA.
A4 Study Team
Insight 46 Study Team
Australian Imaging Biomarkers and Lifestyle (AIBL) Study
Alzheimer's Disease Neuroimaging Initiative
Stanford University · USStanford Medicine · USBrigham and Women's Hospital · USEdith Cowan University · AUMRC Unit for Lifelong Health and Ageing · GBUniversity College London · GBUK Dementia Research Institute · GB
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MVascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI REISA A. SPERLING · 2010 to 2026
$50.2MAnti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8MStanford Alzheimer's Disease Research CenterAdmin Supp: Developing iPSC models for AD and PDP30AG066515 · NIA · STANFORD UNIVERSITY · PI Jennifer Kaci Fairchild · 2020 to 2026
$29.0MWorking Memory in Parkinson Disease: A Cognitive & Systems Neuroscience ApproachP50AG047366 · NIA · STANFORD UNIVERSITY · PI HENDERSON, VICTOR · 2015 to 2019
$7.9MStanford Medicine Center for Longevity and Healthy Aging Research Education CoreP30AG059307 · NIA · STANFORD UNIVERSITY · PI ZOU, JAMES · 2018 to 2025
$4.9MStatistical and computational methods for integrative analysis of Alzheimer's Disease geneticsR01AG066206 · NIA · STANFORD UNIVERSITY · PI HE, ZIHUAI · 2019 to 2023
$3.5MThe Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) CohortR01AG060747 · NIA · STANFORD UNIVERSITY · PI GREICIUS, MICHAEL D · 2018 to 2022
$3.4MImmunogenetic contribution to the progression of preclinical Alzheimer's diseaseK23AG062750 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI YANG, HYUN-SIK · 2019 to 2023
$982kCIHRMedical Research Council MC_UU_12019/1Medical Research Council MC_UU_12019/3Medical Research Council MR/L016311/1NIA NIH HHS K23 AG062750NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG066515NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG060747NIA NIH HHS R01 AG063689NIA NIH HHS R01 AG066206NIA NIH HHS U01 AG024904Wellcome TrustWellcome Trust 200109/Z/15/Z
Abstract
KLOTHO∗VS heterozygosity (KL∗VS
Indexed as
Carrier StateHeterozygoteAgedAged, 80 and overAlzheimer DiseaseAmyloidogenic ProteinsApolipoprotein E4BrainFemaleGlucuronidaseHumansKlotho ProteinsMaleMiddle AgedPositron-Emission TomographyRiskAmyloidogenic ProteinsApolipoprotein E4GlucuronidaseKlotho ProteinsAlzheimer's diseaseAmyloidAPOE4HeterozygosityKLOTHOPETPre-clinical
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.